Literature DB >> 22414869

Modafinil inhibits K(Ca)3.1 currents and muscle contraction via a cAMP-dependent mechanism.

Shinkyu Choi1, Moon Young Kim, Ka Young Joo, Seonghee Park, Ji Aee Kim, Jae-Chul Jung, Seikwan Oh, Suk Hyo Suh.   

Abstract

Modafinil has been used as a psychostimulant for the treatment of narcolepsy. However, its primary mechanism of action remains elusive. Therefore, we examined the effects of modafinil on K(Ca)3.1 channels and vascular smooth muscle contraction. K(Ca)3.1 currents and channel activity were measured using a voltage-clamp technique and inside-out patches in mouse embryonic fibroblast cell line, NIH-3T3 fibroblasts. Intracellular adenosine 3',5'-cyclic monophosphate (cAMP) concentration was measured, and the phosphorylation of K(Ca)3.1 channel protein was examined using western blotting in NIH-3T3 fibroblasts and/or primary cultured mouse aortic smooth muscle cells (SMCs). Muscle contractions were recorded from mouse aorta and rat pulmonary artery by using a myograph developed in-house. Modafinil was found to inhibit K(Ca)3.1 currents in a concentration-dependent manner, and the half-maximal inhibition (IC(50)) of modafinil for the current inhibition was 6.8 ± 0.7 nM. The protein kinase A (PKA) activator forskolin also inhibited K(Ca)3.1 currents. The inhibitory effects of modafinil and forskolin on K(Ca)3.1 currents were blocked by the PKA inhibitors PKI(14-22) or H-89. In addition, modafinil relaxed blood vessels (mouse aorta and rat pulmonary artery) in a concentration-dependent manner. Modafinil increased cAMP concentrations in NIH-3T3 fibroblasts or primary cultured mouse aortic SMCs and phosphorylated K(Ca)3.1 channel protein in NIH-3T3 fibroblasts. However, open probability and single-channel current amplitudes of K(Ca)3.1 channels were not changed by modafinil. From these results, we conclude that modafinil inhibits K(Ca)3.1 channels and vascular smooth muscle contraction by cAMP-dependent phosphorylation, suggesting that modafinil can be used as a cAMP-dependent K(Ca)3.1 channel blocker and vasodilator.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22414869     DOI: 10.1016/j.phrs.2012.02.009

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  5 in total

1.  cAMP-PKA inhibition of SK3 channel reduced both Ca2+ entry and cancer cell migration by regulation of SK3-Orai1 complex.

Authors:  Lucie Clarysse; Maxime Guéguinou; Marie Potier-Cartereau; Grégoire Vandecasteele; Philippe Bougnoux; Stephan Chevalier; Aurélie Chantôme; Christophe Vandier
Journal:  Pflugers Arch       Date:  2014-01-24       Impact factor: 3.657

2.  Modafinil improves monocrotaline-induced pulmonary hypertension rat model.

Authors:  Hyeryon Lee; Kwan Chang Kim; Min-Sun Cho; Suk-Hyo Suh; Young Mi Hong
Journal:  Pediatr Res       Date:  2016-03-09       Impact factor: 3.756

3.  Protein Kinase A-Mediated Suppression of the Slow Afterhyperpolarizing KCa3.1 Current in Temporal Lobe Epilepsy.

Authors:  Manindra Nath Tiwari; Sandesh Mohan; Yoav Biala; Yoel Yaari
Journal:  J Neurosci       Date:  2019-10-31       Impact factor: 6.167

Review 4.  Structure, Gating and Basic Functions of the Ca2+-activated K Channel of Intermediate Conductance.

Authors:  Luigi Sforna; Alfredo Megaro; Mauro Pessia; Fabio Franciolini; Luigi Catacuzzeno
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

5.  Novel phenolic inhibitors of small/intermediate-conductance Ca²⁺-activated K⁺ channels, KCa3.1 and KCa2.3.

Authors:  Aida Oliván-Viguera; Marta Sofía Valero; María Divina Murillo; Heike Wulff; Angel-Luis García-Otín; José-Miguel Arbonés-Mainar; Ralf Köhler
Journal:  PLoS One       Date:  2013-03-14       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.